FIGURE 2
Effect of selected antipsychotics on body weight: Antipsychotic-naïve patients were put on olanzapine in combination with escitalopram, diazepam (STAT, I.V) and haloperidol (STAT, I.M) (OLEDH, n=8), quetiapine (QUET, n=8), olanzapine (OLAN, n=8), risperidone (RISP, n=8), aripiprazole (n=8) or haloperidol (n=8) in therapeutic doses for an average time period of 39, 40, 45, 38, 30 and 33 days respectively showing no significant change in body weight as compared to antipsychotics-naïve patients (n=8) (ANOVA followed by Bonferroni’s Multiple Comparison Test) (P > 0.05).
FIGURE 1
Effect of selected antipsychotics on random blood glucose: Antipsychotic-naïve patients were put on olanzapine in combination with escitalopram, diazepam (STAT, I.V) and haloperidol (STAT, I.M) (OLEDH, n=8), quetiapine (QUET, n=8), olanzapine (OLAN, n=8), risperidone (RISP, n=8), aripiprazole (n=8) or haloperidol (n=8) in therapeutic doses for an average time period of 39, 40, 45, 38, 30 and 33 days respectively showing no significant change in random blood glucose as compared to antipsychotics-naïve patients (n=8) (ANOVA followed by Bonferroni’s Multiple Comparison Test) (P > 0.05).
FIGURE 3
Effect of selected antipsychotics on insulin: Antipsychotic-naïve patients were put on olanzapine in combination with esitalopram, diazepam (STAT, I.V) and haloperidol (STAT, I.M) (OLEDH, n=8), quetiapine (QUET, n=8), olanzapine (OLAN, n=8), risperidone (RISP, n=8), aripiprazole (n=8) or haloperidol (n=8) in therapeutic doses for an average time period of 39, 40, 45, 38, 30 and 33 days respectively showing no significant change in insulin as compared to antipsychotics-naïve patients (ANOVA followed by Bonferroni’s Multiple Comparison Test) (P > 0.05).
FIGURE 4
Effect of selected antipsychotics on c-peptide: Antipsychotic-naïve patients were put on olanzapine in combination with esitalopram, diazepam (STAT, I.V) and haloperidol (STAT, I.M) (OLEDH, n=8), quetiapine (QUET, n=8), olanzapine (OLAN, n=8), risperidone (RISP, n=8), aripiprazole (n=8) or haloperidol (n=8) in therapeutic doses for an average time period of 39, 40, 45, 38, 30 and 33 days respectively showing no significant change in c-peptide as compared to antipsychotics-naïve patients (ANOVA followed by Bonferroni’s Multiple Comparison Test) (P > 0.05).
FIGURE 5
Assessment of beta cells function (%β): Antipsychotic-naïve patients were treated with olanzapine in combination with escitalopram, diazepam (STAT, I.V) and haloperidol (STAT, I.M) (OLEDH, n=8), quetiapine (QUET, n=8), olanzapine (OLAN, n=8), risperidone (RISP, n=8), aripiprazole (n=8) or haloperidol (n=8) in therapeutic doses for an average time period of 39, 40, 45, 38, 30 and 33 days respectively showing no significant change in%β as compared to antipsychotics-naïve patients (ANOVA followed by Bonferroni’s Multiple Comparison Test) (P > 0.05).
FIGURE 6
Assessment of beta insulin resistance (IR): Antipsychotic-naïve patients were treated with olanzapine in combination with escitalopram, diazepam (STAT, I.V) and haloperidol (STAT, I.M) (OLEDH, n=8), quetiapine (QUET, n=8), olanzapine (OLAN, n=8), risperidone (RISP, n=8), aripiprazole (n=8) or haloperidol (n=8) in therapeutic doses for an average time period of 39, 40, 45, 38, 30 and 33 days respectively showing no significant change in IR as compared to antipsychotics-naive patients (ANOVA followed by Bonferroni’s Multiple Comparison Test) (P > 0.05).
FIGURE 7
Effect of selected antipsychotics on cholesterol: Antipsychotic-naïve patients were treated with olanzapine in combination with escitalopram, diazepam (STAT, I.V) and haloperidol (STAT, I.M) (OLEDH, n=8), or quetiapine (QUET, n=8), olanzapine (OLAN, n=8), risperidone (RISP, n=8), aripiprazole (n=8) or haloperidol (n=8) in therapeutic doses for an average time period of 39, 40, 45, 38, 30 and 33 days respectively showing significant elevation in choleterole of aripiprazole treated group as compared to antipsychotics-naive patients (ANOVA followed by Bonferroni’s Multiple Comparison Test) (*P<0.05).
FIGURE 8
Effect of selected antipsychotics on triglycerides (TGs): Antipsychotic-naïve patients were treated with olanzapine in combination with escitalopram, diazepam (STAT, I.V) and haloperidol (STAT, I.M) (OLEDH, n=8), or quetiapine (QUET, n=8), olanzapine (OLAN, n=8), risperidone (RISP, n=8), aripiprazole (n=8) or haloperidol (n=8) in therapeutic doses for an average time period of 39, 40, 45, 38, 30 and 33 days respectively showing no significant elevation in triglycerides as compared to antipsychotics-naive patients (ANOVA followed by Bonferroni’s Multiple Comparison Test) (*P<0.05).
FIGURE 9
Effect of selected antipsychotics on enzymes: Antipsychotic-naïve patients were treated with olanzapine in combination with escitalopram, diazepam (STAT, I.V) and haloperidol (STAT, I.M) (OLEDH, n=8), or quetiapine (QUET, n=8), olanzapine (OLAN, n=8), risperidone (RISP, n=8), aripiprazole (n=8) or haloperidol (n=8) in therapeutic doses for an average time period of 39, 40, 45, 38, 30 and 33 days respectively showing significant elevation in ALT (a) and AST (b) in haloperidol treated groups as compared to antipsychotics-naive, significant elevation in amylase (c) of combination group (**P < 0.01), olanzapine (*P < 0.05) and aripiprazole treated groups (**P < 0.01) as compared to antipsychotics-naïve patients. Significant elevation was observed in lipase (d) of combination group (***P < 0.001) and risperidone treated group (***P < 0.01) as compared to antipsychotics-naïve patients. No significant change in CPK (e) as compared to antipsychotics-naïve patients was noticed (P > 0.05) (ANOVA followed by Bonferroni’s Multiple Comparison Test).
FIGURE 10
Effect of selected antipsychotics on blood urea (a) and serum creatinine (b): Antipsychotic-naïve patients were treated with olanzapine in combination with escitalopram, diazepam (STAT, I.V) and haloperidol (STAT, I.M) (OLEDH, n=8), or quetiapine (QUET, n=8), olanzapine (OLAN, n=8), risperidone (RISP, n=8), aripiprazole (n=8) or haloperidol (n=8) in therapeutic doses for an average time period of 39, 40, 45, 38, 30 and 33 days respectively showing no significant change in blood urea and serum creatinine as compared to antipsychotics-naïve patients (*P < 0.05) (ANOVA followed by Bonferroni’s Multiple Comparison Test).